N-(1,3-benzothiazol-2-yl)-2-(4{[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-1,3-thiazol-2-yl)-1,2,3,4-tetrahydroisoquinoline-8-carboxamide | 1565760-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1,3-benzothiazol-2-yl)-2-(4{[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-1,3-thiazol-2-yl)-1,2,3,4-tetrahydroisoquinoline-8-carboxamide
• 英文别名: N-(1,3-benzothiazol-2-yl)-2-(4-{[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-1,3-thiazol-2-yl)-1,2,3,4-tetrahydroisoquinolin-8-carboxamide；2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-1,3-thiazole-4-carboxamide
• CAS: 1565760-04-4
• 化学式: C₄₁H₄₀N₈O₇S₄
• 分子量: 885.082
• InChiKey: LCRLAKQIEIMENB-MUUNZHRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  60
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  282
• 氢给体数：
  3
• 氢受体数：
  15

文献信息

• [EN] APOPTOSIS-INDUCING AGENTS<br/>[FR] AGENTS INDUISANT L'APOPTOSE
  申请人：ABBVIE INC

  公开号：WO2014028381A1

  公开（公告）日：2014-02-20

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti apoptotic Bcl-xL protein.

  本文披露了抑制抗凋亡Bcl-xL蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-xL蛋白的疾病的方法。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20140073640A1

  公开（公告）日：2014-03-13

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  本发明涉及抑制抗凋亡Bcl-xL蛋白活性的化合物、含有该化合物的组合物以及治疗表达抗凋亡Bcl-xL蛋白的疾病的方法。
• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• APOPTOSIS-INDUCING AGENTS
  申请人：AbbVie Inc.

  公开号：EP2882439A1

  公开（公告）日：2015-06-17
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.